Pluristem to develop stem cell therapy on its own: CEO

Anand Basu, Reuters Pluristem is an Israeli company that is publicly traded on NASDAQ and has been working on a “universal donor” stem cell therapy that originates from cord blood mesenchymal stem cells. Key to Pluristem’s intellectual property are a series of patents on three dimensional bioreactors that allow for mass production of these cells….

Pluristem to take part in EU stem cell study

(Shiri Habib-Valdhorn, Globes [online], Israel business news) Broadly speaking there are two types of adult stem cell therapies: Those that involve the use of the patient’s own stem cells, called autologous, and those that involve use of another patient’s cells, called allogeneic. There are pros and cons to both approaches. In the autologous approach the…